ReviewPaediatric drugs2012
Current and future management strategies for relapsed or progressive hepatoblastoma.
Review in Paediatric drugs, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 24 citations in OpenAlex.
- SKP2 ubiquitylation modifies IDH1 to regulate hepatoblastoma cell cycle and glucose metabolism.BMC cancer · 2025Article
- Construction and validation of nomogram prognostic model for predicting survival in hepatoblastoma patients: a population-based study.Updates in surgery · 2024Article
- Hepatoblastoma Relapse-Findings from the German HB99 Trial and the German Liver Tumor Registry.Cancers · 2024Article
- Article
- Repeat hepatectomy for pediatric recurrent chemotherapy-resistant hepatoblastoma: a report of 18 cases.Journal of cancer research and clinical oncology · 2023Article
- Treatment optimization for recurrent hepatoblastoma: retrospective study from a hepatoblastoma cohort in Southern China.Pediatric surgery international · 2022Article
- Long noncoding RNA PVT1 promotes hepatoblastoma cell proliferation through activating STAT3.Cancer management and research · 2019Article
- Low dosage of arsenic trioxide inhibits vasculogenic mimicry in hepatoblastoma without cell apoptosis.Molecular medicine reports · 2018Article
- Magnetic resonance imaging of primary pediatric liver tumors.Pediatric radiology · 2016Review
- Hepatoblastoma: A Need for Cell Lines and Tissue Banks to Develop Targeted Drug Therapies.Frontiers in pediatrics · 2016Review
- The role of BH3-mimetic drugs in the treatment of pediatric hepatoblastoma.International journal of molecular sciences · 2015Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 4 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hepatoblastoma is the most common primary malignant neoplasm of the liver in children. Improvements in chemotherapy and surgical techniques have increased survival rates for those with localized disease. The prognosis for patients with progressive or relapsed disease continues to be dismal. Complete resection by surgery or liver transplantation is necessary for cure. Few conventional chemotherapy agents have demonstrated activity in progressive or relapsed hepatoblastoma. Irinotecan has shown activity in relapsed and progressive hepatoblastoma. The efficacy of high-dose chemotherapy in this setting is unknown. Newer targeted agents that 'selectively' interfere with pathway targets involved in tumor growth and progression such as insulin-like growth factor, phosphatidylinositol 3-kinase (PI3K), Akt, and mammalian target of rapamycin (mTOR) are currently under development. Because of the rarity of hepatoblastoma, only a small minority of these agents will ever be evaluated in children with this disorder. Gene-directed therapy and immunotherapy have shown promising results in the preclinical setting, and should be investigated as future treatment options for advanced hepatoblastoma.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.